Jane Street Group, LLC Selecta Biosciences Inc Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.62 - $0.85 $64,794 - $88,830	104,507 Added 121.94%	190,211 $159,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.35 $57,421 - $115,700	85,704 New	85,704 $59,000
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.4 $171,010 - $230,206	-164,433 Reduced 91.33%	15,605 $17,000
Q1 2023 May 15, 2023	BUY	$1.15 - $1.89 $207,043 - $340,271	180,038 New	180,038 $250,000
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $6,434 - $12,578	4,838 Added 14.49%	38,228 $63,000
Q2 2022 Aug 16, 2022	BUY	$0.67 - $1.4 $14,835 - $30,998	22,142 Added 196.85%	33,390 $44,000
Q1 2022 May 17, 2022	SELL	$1.23 - $3.31 $87,278 - $234,870	-70,958 Reduced 86.32%	11,248 $14,000
Q4 2021 Feb 15, 2022	BUY	$2.89 - $4.43 $202,733 - $310,764	70,150 Added 581.87%	82,206 $268,000
Q3 2021 Nov 16, 2021	SELL	$3.36 - $4.62 $41,496 - $57,057	-12,350 Reduced 50.6%	12,056 $50,000
Q2 2021 Aug 16, 2021	BUY	$2.82 - $5.01 $68,824 - $122,274	24,406 New	24,406 $102,000
Q1 2021 May 18, 2021	SELL	$2.92 - $5.07 $40,576 - $70,452	-13,896 Closed	0 $0
Q4 2020 Feb 17, 2021	SELL	$1.64 - $3.42 $11,279 - $23,522	-6,878 Reduced 33.11%	13,896 $42,000
Q3 2020 Nov 17, 2020	SELL	$2.18 - $2.84 $322,016 - $419,507	-147,714 Reduced 87.67%	20,774 $51,000
Q2 2020 Aug 17, 2020	BUY	$1.83 - $4.06 $116,086 - $257,546	63,435 Added 60.38%	168,488 $478,000
Q1 2020 May 15, 2020	BUY	$1.5 - $4.52 $157,579 - $474,839	105,053 New	105,053 $253,000
Q3 2019 Nov 14, 2019	SELL	$1.6 - $2.08 $174,350 - $226,655	-108,969 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$1.79 - $3.05 $195,054 - $332,355	108,969 New	108,969 $195,000

Others Institutions Holding SELB

# of Institutions

Shares Held

4.67M

Call Options Held

Put Options Held

View Full List

About SELECTA BIOSCIENCES INC

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

More about SELB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account